HROW vs URGN: Which Stock Is the Better Buy?
Harrow, Inc. and UroGen Pharma Ltd. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — HROW vs URGN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Harrow, Inc. (HROW) | UroGen Pharma Ltd. (URGN) | |
|---|---|---|
| Market cap | $1.4B | $1.4B |
| Revenue (latest FY) | $272.30M | $109.79M |
| Net income (latest FY) | $-5.14M | $-153.49M |
| Revenue growth (5y CAGR) | 41.0% | 56.2% |
| Net margin | -1.9% | -139.8% |
| Return on equity | -9.8% | 145.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | Yes | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full HROW vs URGN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open HROW's full financials → Open URGN's full financials →More comparisons
Frequently asked questions
Which is bigger, HROW or URGN?
UroGen Pharma Ltd. is larger by market capitalization — $1.4B versus $1.4B.
Which grows faster, HROW or URGN?
Over the last five fiscal years, UroGen Pharma Ltd. grew revenue faster — 56.2%/yr versus 41.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.